Glycopyrronium

Glycopyrronium

SCHEMBL417980

C[N+]1(C)CC[C@@H](OC(=O)[C@@](O)(c2ccccc2)C2CCCC2)C1.[Br-]

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

CHRM1CHRM2CHRM3CHRM4CHRM5

The experimentally established mechanism targets of Glycopyrronium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRM3 known ✓ P20309 15/20 1.00
CHRM2 known ✓ P08172 8/20 1.00
CHRM4 known ✓ P08173 1/20 1.00
CHRM5 known ✓ P08912 1/20 1.00
CHRM1 known ✓ P11229 1/20 1.00
KCNH2 Q12809 2/20 1.00
HRH1 P35367 1/20 1.00
HTR2B P41595 1/20 1.00
SLC22A1 O15245 1/20 0.65
LMNA P02545 1/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
SLC6A4 P31645 1/20 0.62
ALDH1A1 P00352 1/20 0.61
CYP1A2 P05177 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Glycopyrronium SCHEMBL41436 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL1900235 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL2012259 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL417981 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL132614 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL2335685 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL131054 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Glycopyrronium SCHEMBL4106576 1.00 CHRM3 (1.00) CHRM3CHRM2KCNH2CHRM4CHRM5
Hexopyrronium SCHEMBL5391795 0.99 CHRM3 (0.98) CHRM3CHRM2KCNH2CHRM4CHRM5
Hexopyrronium SCHEMBL915388 0.99 CHRM3 (0.98) CHRM3CHRM2KCNH2CHRM4CHRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250255794-A1 TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2025-08-14 US claimed
US-12357568-B2 Aerosol formulation for COPD CHIESI FARMACEUTICI S.P.A. (IT) 2025-07-15 US claimed
EP-4333831-B1 TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL (DE) 2024-08-14 EP claimed
EP-4260852-A1 TOPICAL FORMULATION OF AN ANTICHOLINERGIC COMPOUND FOR TREATING SEVERE HYPERHIDROSIS AND EXCESSIVE SWEATING Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) 2023-10-18 EP claimed
US-11590074-B2 Aerosol formulation for COPD CHIESI FARMACEUTICI S.P.A. (IT) 2023-02-28 US claimed
US-11191713-B2 Oil in water emulsion DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2021-12-07 US claimed
US-20210290536-A1 TOPICAL EMULSION OF AN ANTICHOLINERGIC COMPOUND DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2021-09-23 US claimed
US-20210000738-A1 AEROSOL FORMULATION FOR COPD CHIESI FARMACEUTICI S.P.A. (IT) 2021-01-07 US claimed
US-10806701-B2 Aerosol formulation for COPD CHIESI FARMACEUTICI S.P.A. (IT) 2020-10-20 US claimed
US-20200101005-A1 Oil in Water Emulsion DR. AUGUST WOLFF GMBH & CO. KG ARZNEIMITTEL (DE) 2020-04-02 US claimed
EP-3431072-B1 OIL IN WATER EMULSION DR AUGUST WOLFF GMBH & CO KG ARZNEIMITTEL (DE) 2019-11-06 EP claimed
EP-3431072-A1 OIL IN WATER EMULSION Dr. August Wolff GmbH & Co. KG Arzneimittel (DE) 2019-01-23 EP claimed
US-10159645-B2 Combination therapy for COPD CHIESI FARMACEUTICI S.P.A. (IT) 2018-12-25 US claimed
US-10098837-B2 Combination therapy for COPD CHIESI FARMACEUTICI S.P.A. (IT) 2018-10-16 US claimed
EP-2417106-B1 PROCESS FOR PREPARING PYRROLIDINIUM SALTS NOVARTIS AG (CH) 2016-11-30 EP claimed
US-20120022127-A1 PROCESS FOR PREPARING PYRROLIDINIUM SALTS NOVARTIS AG (CH) 2012-01-26 US claimed
WO-2009142589-A1 COMBINATION OF (A) GLUCOCORTICOID RECEPTOR MODULATOR AND (B) A MUSCARINIC ANTAGONIST ASTRAZENECA AB (SE) 2009-11-26 WO claimed
US-20250262151-A1 AEROSOL FORMULATION FOR COPD CHIESI FARMACEUTICI S.P.A. (IT) 2025-08-21 US disclosed
WO-2007027134-A1 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS ASTRAZENECA AB (SE) 2007-03-08 WO disclosed
WO-2007027133-A1 7-(2-AMINO-1-HYDROXY-ETHYL)-4-HYDROXYBENZOTHIAZOL-2(3H)-ONE-DERIVATIVES AS β2 ADRENOCEPTOR AGONISTS ASTRAZENECA AB (SE) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022127-A1 PROCESS FOR PREPARING PYRROLIDINIUM SALTS C1S, C1R, C9 CHRM3 616/4885CHRM2 172/4885CHRM4 731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.